Alyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, Liza My Gelissen, E Hoitsma, Esther Mpe Zeinstra, Luuk C van Rooij, Caspar Ep van Munster, Anke Vennegoor, Jop P Mostert, Beatrijs Ha Wokke, Nynke F Kalkers, Erwin Lj Hoogervorst, Jeroen Jj van Eijk, Christiaan M Roosendaal, Jolijn J Kragt, Marijke Eurelings, Jessie van Genugten, Jessica Nielsen, Lgf Sinnige, Mark E Kloosterziel, Edo Pj Arnoldus, Gert W van Dijk, Willem H Bouvy, Eva Mm Strijbis, Bob W van Oosten, Brigit A de Jong, Bernard Mj Uitdehaag, Theo Rispens, Joep Killestein, Zoé LE van Kempen, Charlotte E Teunissen
{"title":"纳他珠单抗治疗的多发性硬化症患者血清神经丝蛋白和胶质纤维酸性蛋白水平与消退症状无关。","authors":"Alyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, Liza My Gelissen, E Hoitsma, Esther Mpe Zeinstra, Luuk C van Rooij, Caspar Ep van Munster, Anke Vennegoor, Jop P Mostert, Beatrijs Ha Wokke, Nynke F Kalkers, Erwin Lj Hoogervorst, Jeroen Jj van Eijk, Christiaan M Roosendaal, Jolijn J Kragt, Marijke Eurelings, Jessie van Genugten, Jessica Nielsen, Lgf Sinnige, Mark E Kloosterziel, Edo Pj Arnoldus, Gert W van Dijk, Willem H Bouvy, Eva Mm Strijbis, Bob W van Oosten, Brigit A de Jong, Bernard Mj Uitdehaag, Theo Rispens, Joep Killestein, Zoé LE van Kempen, Charlotte E Teunissen","doi":"10.1177/13524585241293940","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of natalizumab wearing-off symptoms (WoSs).</p><p><strong>Objectives: </strong>We investigated the longitudinal association between and predictive value of sNfL and sGFAP and the occurrence of WoS in MS patients treated with natalizumab.</p><p><strong>Methods: </strong>We performed longitudinal measurements of sNfL and sGFAP in NEXT-MS trial participants who completed a questionnaire about WoS.</p><p><strong>Results: </strong>A total of 364 participants were included. In total, 55.5% presented with WoS and 44.5% without WoS during natalizumab treatment. Longitudinal analyses showed no association between sNfL and sGFAP levels and WoS at any timepoint. Biomarker levels at baseline did not predict first-time WoS occurrence.</p><p><strong>Conclusion: </strong>Acute and chronic neuronal and axonal damage are most likely not the underlying cause of WoS.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.\",\"authors\":\"Alyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, Liza My Gelissen, E Hoitsma, Esther Mpe Zeinstra, Luuk C van Rooij, Caspar Ep van Munster, Anke Vennegoor, Jop P Mostert, Beatrijs Ha Wokke, Nynke F Kalkers, Erwin Lj Hoogervorst, Jeroen Jj van Eijk, Christiaan M Roosendaal, Jolijn J Kragt, Marijke Eurelings, Jessie van Genugten, Jessica Nielsen, Lgf Sinnige, Mark E Kloosterziel, Edo Pj Arnoldus, Gert W van Dijk, Willem H Bouvy, Eva Mm Strijbis, Bob W van Oosten, Brigit A de Jong, Bernard Mj Uitdehaag, Theo Rispens, Joep Killestein, Zoé LE van Kempen, Charlotte E Teunissen\",\"doi\":\"10.1177/13524585241293940\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of natalizumab wearing-off symptoms (WoSs).</p><p><strong>Objectives: </strong>We investigated the longitudinal association between and predictive value of sNfL and sGFAP and the occurrence of WoS in MS patients treated with natalizumab.</p><p><strong>Methods: </strong>We performed longitudinal measurements of sNfL and sGFAP in NEXT-MS trial participants who completed a questionnaire about WoS.</p><p><strong>Results: </strong>A total of 364 participants were included. In total, 55.5% presented with WoS and 44.5% without WoS during natalizumab treatment. Longitudinal analyses showed no association between sNfL and sGFAP levels and WoS at any timepoint. Biomarker levels at baseline did not predict first-time WoS occurrence.</p><p><strong>Conclusion: </strong>Acute and chronic neuronal and axonal damage are most likely not the underlying cause of WoS.</p>\",\"PeriodicalId\":18874,\"journal\":{\"name\":\"Multiple Sclerosis Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multiple Sclerosis Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/13524585241293940\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241293940","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Background: Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of natalizumab wearing-off symptoms (WoSs).
Objectives: We investigated the longitudinal association between and predictive value of sNfL and sGFAP and the occurrence of WoS in MS patients treated with natalizumab.
Methods: We performed longitudinal measurements of sNfL and sGFAP in NEXT-MS trial participants who completed a questionnaire about WoS.
Results: A total of 364 participants were included. In total, 55.5% presented with WoS and 44.5% without WoS during natalizumab treatment. Longitudinal analyses showed no association between sNfL and sGFAP levels and WoS at any timepoint. Biomarker levels at baseline did not predict first-time WoS occurrence.
Conclusion: Acute and chronic neuronal and axonal damage are most likely not the underlying cause of WoS.
期刊介绍：
Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system.
The journal for your research in the following areas:
* __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics
* __Epidemology and genetics:__ genetics epigenetics, epidemiology
* __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures
* __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management
Print ISSN: 1352-4585
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
